Adolescents and adults experienced sustained improvements in eosinophilic esophagitis outcomes with dupilumab for up to 52 weeks, according to research presented at Digestive Disease Week 2023 in Chicago. Patients experienced better histologic, symptomatic and endoscopic outcomes during Part C of the phase 3 LIBERTY-EoE-TREET study despite any previous swallowed topical corticosteroid (STC) use
Fractional exhaled nitric oxide levels predicted treatment response to dupilumab among patients who had uncontrolled moderate to severe asthma, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.Treatment also was effective in patients with type 2 inflammation as well as elevated FeNO and/or elevated eosinophils, Ian D. Pavord, MD, MA, DM, FRCP, FERS,
Patients with atopic dermatitis treated with dupilumab did not experience any significantly increased risk for a primary or recurrent malignancy, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.“A common question that comes up is whether the biologics that we routinely use in clinical practice, such as dupilumab, are safe in this
Patients with asthma and specific eosinophil and IgE levels experienced greater improvements in exacerbations and FEV1 with dupilumab compared with other biologics, according to a study. These results indicate that dupilumab (Dupixent, Sanofi Genzyme/Regeneron) may be a better choice for patients who are eligible for multiple biologics, Ayobami T. Akenroye, MBChB, MPH, PhD, associate physician in
SAN ANTONIO — A high proportion of patients with eosinophilic esophagitis also had simultaneous atopic or allergic comorbid conditions, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.Eosinophilic esophagitis (EoE) is a chronic, progressive type II inflammatory disease, Marc E. Rothenberg, MD, PhD, director of the Cincinnati Center for